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ACINETOBACTER 
Members of the genus Acinetobacter were first described 
by Morax in France and Axenfeld in Germany in 1896, 
and became initially known as the Morax-Axenfeld 
bacillus. Over the years some 15 different generic names 
have been used to describe this microorganism, the 
most common being: Bacterium antitrutum, Herella 
va@nicola, Mima polymorpha, Achrornobacter, Alcaligenes, 
BSl/t: Moraxella lwofii, etc. 
Baumann, Doudoroff and Stainer in 1968 showed 
clearly that the oxidase-negative strains which were 
later given the name Acinetobacter differed from the 
oxidase-positive strains which were later given the name 
Moraxella. 
Today, modern niolecular taxonomic methods have 
resulted in a new classification comprising at least 19 
DNA-DNA homology groups ofwhich, to date, seven 
have been given species names. 
EPIDEMIOLOGY 
Nosocomial infections are a major source for morbidity 
and mortality, and 5 2 5 %  of patients admitted to 
hospitals will develop such infections with staphylo- 
cocci, enterococci and non-fermentative Gram-negative 
bacilli being the most frequent pathogens causing such 
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infections. The sources of these organisms and some of 
the clinical syndromes they cause are shown in Table 1. 
Acinetobacter anitratus is becoming increasingly 
important in that respect. This ubiquitous organism 
is isolated from soil, water, plants and from skin of 
humans, and practically in every faucet and drainage 
system in hospitals which have a high Acinetobacter 
baumanii isolation rate. 
The rate o f h n e t o b a c t e r  baumunii bacteremia in the 
ICU is variable and can vary as much as one hundred 
fold between neighboring centers, nevertheless, figures 
in the range of 0.3-2.0 per 1000 hospitalized patients 
have been reported [l-41 and are considered to con- 
stitute 0.5 to 1% of all nosocomial bacteremias. 
Some 70% of all ICU patients will become 
colonized within their first week of ICU stay with 
Acinetobacter spp., and more in the ensuing weeks [4-51; 
up to 10% of those who are colonized will develop 
bacteremia with Acinetobacter spp. on day 18520  of 
the ICU stay. In 25-33% of the patients, blood cultures 
will grow along with Acinetobacter spp., another niicro- 
organism, most commonly Staphylococcus aureus, or a 
non-fermenting Gram-negative pathogen. 
The incidence of nosocomial infections caused by 
Acinetobacter spp. has an unexplained increase in late 
summer months 16-81, possibly due to the increase in 
ambient humidity and to the fact that these organisms 
grow well in water. 
CLINICAL FEATURES 
The risk factors for the development of Acinetobactev 
baumanii bacteremia have been repeatedly studied (Table 
The clinical picture of the bacteremia may be 
variable and dependent on the underlying disease, 
2) [1,3,4,6,9-121. 
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Table 1 Aerobic Gram-negative bacillary nosocomial infections 
Source Clinical syndrome 
I? juorestens Hospital water Transfusion bacteremia 
I? sfufzeri Contaminated solutions, soil Pseudobacteremia 
I? putida Soil, water, plants CE PID 
B. cepacia Nebulizers, ventilators, disinfectants CF, sepsis in immunosupressed 
B. picketti Water, soil, antiseptics Pseudobactererma, bacteremia 
S. rnaitophiiia Water, soil, milk, food, amoeba Sepsis, cellulitic, meningitis 
Table 2 Acinetobacter banrnanii bacteremia: risk factors 
IV lines 
Broad spectrum AB (3GC:FQs) 
Mechanical ventilation 
Surgical procedures (neurosurgery) 
Fatal underlying disease 
Dialysis 
TPN+ enteral nutrition 
Tracheostomy 
Intravascular catheters 
Procedure performed in an emergency room 
coinfection with an additional pathogen and comorbid 
conditions. 
Complications such as disseminated intravascular 
coagulation (DIC), meningitis and septic pulmonary 
emboli, toxic encephalopathy, and severe MOF may all 
appear and contribute to mortality. 
Septic shock will develop in around 30% of the 
patients with risk factors similar to those that cause 
bacteremia with this pathogen [1,4,12]. 
Acinetobacter bacteremia most commonly arises in 
the ICU patient from the respiratory tract or from 
infected wounds and far less frequently from the 
urinary tract [1,4]. External sources may include con- 
taminated fluids used for dialysis, contaminated pressure 
transducers, etc. [2]. 
An important step that precedes infection in the 
case of Acinetobacter spp. is the colonization of wounds, 
the respiratory tract, the gastrointestinal tract, the 
pharynx and the skin [4,10-121. This is due to the 
particular ability of Acinetobacter spp. to adhere to cells 
and to non-viable surfaces similar to Staphylococcus 
epidermidis. The ability of this organism to form a 
biofilm, and thereby to escape phagocytosis and the kill 
action of some antibiotics, is as yet unknown. 
The mortality in the ICU due to Acinetobacter spp. 
infections is variable. Crude mortality is in the range of 
30-50% and has been reported to reach levels as high 
as 78%. The attributable mortality ranges between 19 
and 25%. 
Risk factors for mortality include: DIC, inappro- 
priate antibiotic therapy, septic shock and MOF, fatal 
underlying diseases and mechanical ventilation. 
Treatment 
The antibiotic resistance of Acinetobacter spp. has been 
adequately documented since 1975, in particular in 
strains isolated from ICU patients. Previous to that 
time, such infections posed no therapeutic problems 
and gentamicin, ampicillin, carbenicillin and nalidixic 
acid alone or in combinations offered adequate therapy. 
Today, most Acinetobacter strains are resistant to amino- 
penicillins, ureidopenicillins, cephalosporins of the 
first, second and third generations, cephamycins and 
most aminoglycosides. Many strains are also resistant to 
tetracyclines, chloramphenicol and the fluoroquino- 
lones. Until recently, imipenem was the most active 
antibiotic, but recent reports describe the appearance 
and spread of strains that are imipenem-resistant 
[13-151. The basis for this high level resistance is the 
low outer membrane permeability of the bacillus, 
coupled with a secondary resistance mechanism such as 
inducible cephalosporinase or antibiotic efflux pump 
which render Acinetobacter highly resistant to most 
antibiotics [16]. 
The treatment of antibiotic-resistant Acinetobacter 
baumanii infections thus remains a dificult therapeutic 
problem. Whenever susceptibility to imipenem/mero- 
penem exists those agents have enjoyed a wide use with 
good therapeutic results. In strains that are imipenem- 
resistant and fluoroquinolone-susceptible the later class 
of agents will become the therapy of choice for the 
adult. In the case of infections with strains that are 
resistant to all known antibiotics, the clinician will 
have no choice but to resort to Polymyxin B [15] or 
sulbactani alone or in combination with trimethoprim 
and sulfonamide [ 18,271. 
Pseudomonas aeruginosa and other Pseudomonas spp. 
Pseudovnonar species are particularly abundant in water 
and soil and are frequently isolated in hospitals. l? 
aeruginora is associated with a high rate of morbidity and 
mortality because of its virulence factors: exotoxin A, 
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Table 3 Sources of community and nosocomial 
I? aerugiiiosa bacteremia 
~ ~ ~ ~ ~ 
Source Community (n=24) Nosocormal ( ~ = 9 6 )  
Urinary 3 (12%) 37 (39%) 
Intra-abdominal - 11 (11%) 
Vascular site 1 (4%) 4 (4%) 
Soft tissue 1 (4%) 4 (4%) 
Meningitir 1 (%) 1 (1%) 
Other/unknown 13 (54%) 23 (23%) 
Respiratoiy 5 (21%) 17 (18%) 
elastase, alkaline phosphatase, phospholipase C, leuko- 
cidin, etc [20]. The other members of the genus, 
because of absence of toxins and invasiveness, are rarely 
associated with bacteremias. 
The sources of nosocomial bacteremias caused by 
I? aevugitzosa are shown in Table 3.  
The urinary tract is an important portal of entry 
for the Pseudomonas spp. while it is rare for the Acine- 
tobactev spp., doubtless because of urinary catheteriza- 
tion, the ability of the Pseudomonas group members to 
live in water and to form a biofilm around catheters, 
and to resist antibiotic action and phagocytosis [20]. 
Due to its virulence, the treatment cfl? aevuxinosa 
infections is a crucial matter. With no therapy the 
attributable mortality may reach 79% while with 
appropriate therapy this rate is 17% (Table 4) [21]. 
Interestingly, the superiority of a synergistic two-drug 
regimen in patients with I! aeruginosa bacteremia cannot 
be shown for non-neutropenic patients (Table 5) [21]. 
It  is interesting to note that over the last 15 years 
(Table 6), the incidence of l? aevuginosa nosocomial 
bacteremia has not changed and is still around 1.5 cases 
per 1000 admissions with a mortality in the range of 
4096, rendering evidence that the progress in antibiotics 
and sepsis care leaves a lot to be desired. 
l? jluorescens has been responsible for a number of 
outbreaks of bacteremia caused by transfusion of 
contaniinated blood or blood products resulting in a 
septic shock due to the large number of the introduced 
organisms [22]. This organism, along with I? stutzeri, 
has also caused pseudobacteremias due to use of 
contaminated skin disinfectants. 
Table 4 Mortality of P aeruginosa bacteremia 
Table 5 Comparison of treatments in P aertlginosa 
bacteremia 
Appropriate Inappropriate No therapy 
No. pts 64 29 19 
Malignancy 27% 56% 26% 
Mean age 69 69 77 
Neutropenia 4% 17% 11% 
Mortality total 27% 48%) 79% 
Attributable mortality 17% 45%) 79% 
Table 6 Comparison of monotherapy to two-drug therapy 
Monotherapy Two d r u g  P-value: 
No. pts. 42 15 
Malignancy 8 (19%) 7 (47%) 0.05 
Age >70 27 (64%) 9 (60%) NS 
Neutropenia 2 (5%) 1 (7%) NS 
Nosocomial 37 (86%) 14 (93%) NS 
Attributable 6 (14%) 2 (13%) NS 
Mortality total 7 (17%) 7 (47%) 0.05 
Burkholderia cepacia (previously named Pseudomonas 
cepacia and Pseudomonas multivovans) is a plant pathogen 
causing sour skin and rotting in onion bulbs, and can 
live and utilize a large variety of carbon sources in- 
cluding industrial wastes, herbicides and even anti- 
biotics [23]. Bacteremia and pseudobacteremia have 
been described due to contamination of povidone- 
iodine solutions but bacteremias originated also from 
contaminated solutions, blood products and instru- 
ments used during surgery [23,25]. Nosocomial endo- 
carditis (as well as endocarditis in iv addicts) have also 
been described [26-281. A problem with this organism 
may be its reduced antibiotic susceptibility which is 
similar to that of Pseudoinonas aevuginosa and Acinefobacter 
baumanii [29]. 
Stenotrophomonas maltophilia (previously known as 
Pseudomonas maltoplzilia or Xanthomonas rnaltophilia) has 
recently emerged as a life-threatening cause of noso- 
comial bacteremias. It is also a free leaving commensal 
isolated froin water, soil, sewage, human feces, plants, 
frozen fish and in the hospital from water faucets, wet 
Baltch Bodry Lechi Gallagher Mallolas Hilf lgra 
Period ‘72-75 72-31 7 - 8 1  80-84 83-89 82-86 90-92 
Iiicidence - 4.7 0.4 1.41 1.4 -1 .h6 
Nosoco. % 97 81 85 6 5 80 77 80 
- 40 Mortality % 63 75 61 
No pts 75 410 60 96 274 200 123 
- - 
Attributable mortality % 44 38 - 48 42 34 37 
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surfaces, spirometers, distilled water, sinks, nebulizers, 
humihfiers, incubators and tissue culture media, but 
also from the hands of personnel and disinfectant 
solutions [21,25]. This organism is presently the second 
most common non-fermenting pathogen (after P 
aeruginosa) isolated from nosocoinial infections. Severe 
bacteremias have been described in immunosuppressed 
patients, e.g. patients with AIDS and neutropenic 
[21,23-251 and in those receiving massive antibiotic 
patients therapy [21]. Endocarditis caused by this 
organism, with constant bacteremia, has been described 
in patients with artificial valves and in iv addicts [21]. 
A major problem with this pathogen is its resistance to 
many antibiotics with a susceptibility pattern that is 
between Acinetobacter spp. and I? aeruginosa [30]. 
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